Peri-operative immunotherapy with OK-432
| Autor: | Mitoshi Yokota, K Miyashita, Daikichi Okada, Sumihiro Tabuchi, Hiroshi Ishikawa, Masao Tomita, Tooru Yasutake, Yoshikazu Mine, Yutaka Tagawa |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Lymphocyte medicine.medical_treatment Population Pharmacology Monoclonal antibody Drug Administration Schedule Picibanil Stomach Neoplasms Internal medicine mental disorders Preoperative Care medicine Humans Intradermal injection education Postoperative Care education.field_of_study MHC class II Hematology biology business.industry Cancer Immunotherapy medicine.disease Combined Modality Therapy Lymphocyte Subsets medicine.anatomical_structure Immunology Injections Intravenous biology.protein business |
| Zdroj: | Biotherapy (Dordrecht, Netherlands). 2(3) |
| ISSN: | 0921-299X |
| Popis: | Pre- and postoperative intradermal administration of OK-432 enhanced the SU-PS skin reaction in patients with gastric cancer, but failed to prevent a fall in the NK activity induced by the operation. The change in NK activity was not associated with a change in the proportion of Leu 7-positive cells, but was related to Leu 11a-positive cells. Intradermal injection of OK-432 increased the proportion of Leu 7-positive cells in the patients in whom they accounted for less than 20% of lymphocyte population. The case was the same with Leu 11a-positive cells. Intravenous injection of OK-432 tended to increase suppressor-inducer T cells (CD4+2HA+ cells), B cells and Leu 7-positive cells. Particularly, the proportions of OK-M1-positive cells and MHC class II antigen-positive cells increased in all patients. Immunotherapy with OK-432 given intravenously at a dose of 0.1 KE appeared to be safe because no side effects were essentially observed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink